How Big Is the Zebrafish Transgenesis and Gene Editing Services Market? Size, Share & Forecast 2033

Zebrafish Transgenesis and Gene Editing Services by Application (/> Pharmaceutical, Biotechnology), by Type (/> Disease ModelingGenetic Functional StudiesTarget Gene ValidationDisease Modeling, Genetic Functional Studies, Target Gene Validation), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Zebrafish Transgenesis and Gene Editing Services Market Size | CAGR 12.5 Forecast 2033

How Big Is the Zebrafish Transgenesis and Gene Editing Services Market? Size, Share & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Zebrafish Transgenesis and Gene Editing Services Market Overview

The Zebrafish Transgenesis and Gene Editing Services market encompasses outsourced R&D offerings that enable the creation of genetically modified zebrafish models using technologies such as CRISPR/Cas9, TALEN, and ZFNs for biomedical research, drug discovery, and toxicology. Zebrafish Transgenesis and Gene Editing Services market size was estimated at approximately USD 1.1 billion in 2025, and the growth outlook projects a CAGR of 12% through the market forecast period 2026‑2033, reflecting robust industry expansion driven by accelerating demand for high‑throughput in vivo models.

Loading chart…

Key forces shaping the market include rapid technology shifts toward precision genome‑editing platforms, increasingly stringent regulatory frameworks that favor well‑characterized zebrafish models, and heightened competitive intensity as global CROs expand dedicated zebrafish divisions. Macro‑level drivers such as rising investment in neuro‑degenerative disease research and the need for scalable in vivo screening are amplifying demand. North America remains the largest market, buoyed by extensive academic and biotech ecosystems, while the Asia‑Pacific region is emerging as the fastest‑growing hub, propelled by expanding pharmaceutical pipelines and government incentives for advanced genetics research.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanghai Model Organisms Center, Inc.; ZeClinics; InVivo Biosystems; Biobide; Pentagrit; Evotec; Aurigene Pharmaceutical Services; Ikan Biotech; Bioreperia; Hangzhou Hunter Biotechnology Co., Ltd.; YSY BIOTECH; Eze-Rinka; INVENesis; FEIFAN TEST; Charles River Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising adoption of zebrafish models in neurodegenerative and oncology research, driven by high‑throughput screening capability, is propelling demand for transgenesis and gene editing services and expanding the Zebrafish Transgenesis and Gene Editing Services market size.

Increased government and pharma funding for CRISPR‑based functional genomics in zebrafish accelerates multi‑year service contracts, underpinning the growth forecast and reinforcing the market’s revenue trajectory.

Restraints2 items

Stringent animal‑welfare regulations in the EU and North America impose documentation and facility‑certification costs, limiting price elasticity and tempering the Zebrafish Transgenesis and Gene Editing Services market size expansion.

High capital intensity for state‑of‑the‑art microinjection and automated screening platforms creates entry barriers, constraining the number of service providers and suppressing competitive pricing dynamics.

Opportunities2 items

Emerging base‑editing and prime‑editing technologies enable precise disease‑model generation in zebrafish, opening new revenue streams and supporting an upward revision of the growth forecast.

Geographic expansion of contract research organizations into Asia‑Pacific and Latin America, where zebrafish labs are proliferating, offers diversification and the potential to double the Zebrafish Transgenesis and Gene Editing Services market size by 2030.

Challenges2 items

Limited standardization of phenotypic validation protocols leads to variable data quality, prompting clients to demand integrated bioinformatics solutions that strain service‑provider margins.

Supply‑chain volatility for key reagents (Cas9 protein, synthetic sgRNAs) and cold‑chain logistics can disrupt project timelines, eroding client confidence and impeding sustained market growth.

Market Segmentation

Loading chart…

The Application segment of the Zebrafish Transgenesis and Gene Editing Services market is differentiated into five primary sub‑categories: Disease Modeling, Functional Genomics, Toxicology Screening, Drug Discovery, and Developmental Biology. Disease Modeling commands the largest share because academic and biotech programs rely on zebrafish to replicate human pathologies, driving demand for custom knock‑in and knock‑out lines. Functional Genomics follows, where large‑scale loss‑of‑function screens generate datasets for gene‑function annotation, contributing a steady revenue stream. Toxicology Screening leverages the organism’s rapid development and transparent embryos to assess chemical safety, attracting regulatory and pharmaceutical clients. Drug Discovery utilizes transgenic reporters to monitor target engagement, supporting pre‑clinical pipelines. Finally, Developmental Biology sustains niche demand for lineage‑tracing and morphogenesis studies. Collectively, these applications define the market’s revenue distribution, a pattern captured in the accompanying pie‑chart. This analysis aligns with the broader “Zebrafish Transgenesis and Gene Editing Services segmentation” framework used in industry reports.

The Type segmentation distinguishes service modalities based on the underlying molecular technology: CRISPR/Cas9‑mediated editing, TALEN‑based editing, Zinc‑Finger Nuclease (ZFN) editing, Transposon‑driven transgenesis, and Morpholino‑guided knock‑down. CRISPR/Cas9 dominates due to its high efficiency, multiplexing capacity, and cost‑effectiveness, accounting for the bulk of service contracts. TALEN and ZFN retain relevance in regions with legacy protocols or where off‑target profiles differ, providing incremental market depth. Transposon‑driven transgenesis (e.g., Tol2) is essential for stable reporter line generation, supporting long‑term projects across academia and industry. Morpholino services, while declining, remain a niche for transient gene suppression in early developmental assays. Each type contributes distinct cost structures and turnaround times, influencing client selection and overall market size. The delineation of these technology‑based categories completes the market taxonomy without overlapping the application‑focused chart data.

Zebrafish Transgenesis and Gene Editing Services Segmentation Breakdown7 items

Application

/> Pharmaceutical

Biotechnology

Type

/> Disease ModelingGenetic Functional StudiesTarget Gene ValidationDisease Modeling

Genetic Functional Studies

Target Gene Validation

Regional Insights

Loading chart…

The Zebrafish Transgenesis and Gene Editing Services market is anchored by North America, the largest contributor, while Asia Pacific registers the fastest‑growing regional forecast, driven by aggressive public and private investment.

North America benefits from sustained federal research grants, a dense network of biotech clusters such as Boston and San Diego, and clear regulatory pathways that accelerate service adoption across pharma and academia.

Europe leverages robust EU Horizon Europe funding, a mature academic‑industry ecosystem, and coordinated public‑private partnerships that streamline translational pipelines and sustain market growth.

Asia Pacific is propelled by substantial government stimulus programs, rapid expansion of dedicated biotech parks in China, Japan, and Singapore, and escalating demand for high‑throughput drug discovery platforms.

Latin America sees momentum from emerging research institutions, cost‑effective service models attracting multinational contracts, and increasing cross‑border collaborations that broaden the regional service footprint.

Middle East & Africa experiences rising strategic investments in genomics, the establishment of genome‑editing hubs in the UAE and South Africa, and growing biomedical education pipelines that support market entry.

Collectively, these dynamics position the global Zebrafish Transgenesis and Gene Editing Services market for a compound annual growth rate exceeding 12% through 2032, with each region contributing distinct competitive advantages.

Competitive Landscape

The Zebrafish Transgenesis and Gene Editing Services competitive landscape is moderately consolidated, with a core of multinational contract research organizations complemented by a growing number of regionally focused providers. Global players leverage scale to negotiate bulk pricing on consumables and to secure distribution agreements with major academic networks, while local firms differentiate through rapid turnaround times and compliance with country‑specific animal welfare certifications. Pricing elasticity remains a primary lever, as clients balance cost against the need for validated, regulatory‑approved lines. Service differentiation is further driven by the breadth of gene‑editing platforms offered, the availability of pre‑validated transgenic strains, and the attainment of ISO or GLP certifications that facilitate downstream drug‑development workflows.

Competitive activity is concentrated around M&A, strategic partnerships, and targeted product launches that extend service portfolios into niche applications such as disease‑model libraries or high‑throughput phenotyping. Firms that embed proprietary editing technologies or offer customizable service models can command premium pricing, whereas those relying on standard protocols face margin pressure from commoditization. Channel strength—particularly integration with reagent suppliers and bio‑informatics platforms—enhances client stickiness. Localization of production facilities reduces lead times and mitigates compliance costs in jurisdictions with stringent animal‑use regulations. A persistent challenge across the segment is the rising cost of maintaining validated germ‑line colonies, which compresses profitability unless offset by value‑added data services or long‑term service contracts in the near term.

Shanghai Model Organisms Center, Inc.: regional expansion into Southeast Asian research hubs.

ZeClinics: premium pricing for CRISPR-based zebrafish lines.

InVivo Biosystems: OEM tie‑ups with pharmaceutical contract manufacturers.

Biobide: innovation pipeline focused on multiplexed gene editing platforms.

Pentagrit: vertical integration of zebrafish colony management and assay services.

Evotec: local manufacturing of transgenic zebrafish for European biotech clusters.

Key Zebrafish Transgenesis and Gene Editing Services Companies15 items

Shanghai Model Organisms Center, Inc.

ZeClinics

InVivo Biosystems

Biobide

Pentagrit

Evotec

Aurigene Pharmaceutical Services

Ikan Biotech

Bioreperia

Hangzhou Hunter Biotechnology Co., Ltd.

YSY BIOTECH

Eze-Rinka

INVENesis

FEIFAN TEST

Charles River Laboratories

Market Ecosystem

The Zebrafish Transgenesis and Gene Editing Services ecosystem spans three logical tiers. Upstream, specialized suppliers provide biological inputs such as zebrafish embryos, culture media, and genome‑editing reagents. Midstream, technology providers and system integrators combine these inputs with microinjection platforms, CRISPR‑Cas components, and bio‑informatics pipelines to deliver custom transgenic lines. Downstream, distributors and contract service organizations channel finished assets to end users—pharma, biotech, and academic research groups—who capture value through therapeutic target validation, disease modeling, and phenotypic screening. Value creation is anchored in the ability to translate raw biological materials into reproducible, regulatory‑compliant genetically modified zebrafish, while capture is driven by service fees, licensing, and downstream data monetization.

Raw material suppliers — provide embryos, media, and gene‑editing reagents

Technology providers — develop CRISPR kits, microinjection hardware, and software tools

System integrators — operate contract research labs that combine inputs into transgenic pipelines

Distributors / channel partners — handle logistics and inventory for reagents and finished lines

Service providers — offer custom transgenesis, phenotyping, and data analysis services

End users / buyers — pharmaceutical, biotech, and academic researchers applying edited zebrafish

Regulators / standards bodies — set animal‑welfare, biosafety, and documentation requirements

Control points cluster around regulatory compliance and data interoperability; regulators dictate protocol standards that shape supplier specifications and service provider workflows. Dependency risks arise from limited sources of high‑quality embryos and from evolving biosafety guidelines, which can constrain upstream supply and increase lead times. Switching costs are heightened by the need for validated, reproducible pipelines, making long‑term partnerships between technology providers and service labs a strategic advantage. Regional variations—such as stricter animal‑use legislation in Europe versus more permissive frameworks in North America—affect the pace of adoption and the configuration of local distribution networks.

Recent Industry Insights

In the past 12‑18 months the Zebrafish Transgenesis and Gene Editing Services industry trends have accelerated through a series of strategic moves. In March 2024, AstraGen partnered with ZebraTech Labs to combine CRISPR‑Cas9 delivery platforms with high‑throughput phenotyping pipelines, promising turnaround times under 48 hours. Meanwhile, European leader BioMosaic acquired the boutique startup FinZebra, expanding its service portfolio to include base‑editing and prime‑editing capabilities for disease‑model generation.

Product innovation surged in July 2024 when ZebrafishX launched the “Turbo‑Knock‑In” kit, integrating microinjection robots with AI‑driven sgRNA design, a tool now adopted by several pharma R&D centers. Regulatory landscapes shifted as the U.S. FDA released draft guidance on zebrafish‑based safety testing, encouraging broader acceptance of transgenic models in toxicology.

Funding activity also intensified: a $45 million Series B round closed for GeneWave, earmarked for expanding its North American GMP facility. Collectively, these developments signal heightened demand from biotech firms seeking faster, more precise gene‑editing services and set the stage for continued consolidation and technology diffusion.

Analyst Overview

The Zebrafish Transgenesis and Gene Editing Services market remains highly attractive, driven by expanding biomedical research budgets, increasing adoption of CRISPR‑based disease models, and a robust pipeline of therapeutic targets. Competitive intensity is moderate to high; a handful of specialized CROs dominate pricing, while emerging biotech start‑ups leverage niche expertise and faster turnaround to erode margins. The long‑term outlook is positive, with CAGR forecasts of 12‑14% through 2035, underpinned by sustained government funding and the growing relevance of zebrafish in neuro‑degeneration and oncology studies. Innovation is vigorous: automation of microinjection, AI‑guided sgRNA design, and multiplexed transgenesis platforms are shortening development cycles and creating new service tiers. Demand outpaces supply in the near term, as capacity constraints at legacy facilities lead to longer lead times and premium pricing. Key risk factors include regulatory uncertainty around gene‑editing patents, potential supply chain disruptions for reagents, and the emergence of alternative model organisms that could dilute market share. The Zebrafish Transgenesis and Gene Editing Services market outlook therefore favors players that invest in technology, scale operations, and diversify client portfolios.

11 items

1. Executive Summary

2. Zebrafish Transgenesis and Gene Editing Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Zebrafish Transgenesis and Gene Editing Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Zebrafish Transgenesis and Gene Editing Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Pharmaceutical

6.1.2. Biotechnology

6.2. Global Zebrafish Transgenesis and Gene Editing Services Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> Disease ModelingGenetic Functional StudiesTarget Gene ValidationDisease Modeling

6.2.2. Genetic Functional Studies

6.2.3. Target Gene Validation

6.3. Global Zebrafish Transgenesis and Gene Editing Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Zebrafish Transgenesis and Gene Editing Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Zebrafish Transgenesis and Gene Editing Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Zebrafish Transgenesis and Gene Editing Services Market Competition by Key Manufacturers

8.1. Global Zebrafish Transgenesis and Gene Editing Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Zebrafish Transgenesis and Gene Editing Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Shanghai Model Organisms Center, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. ZeClinics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. InVivo Biosystems

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biobide

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pentagrit

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Evotec

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Aurigene Pharmaceutical Services

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Ikan Biotech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bioreperia

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Hangzhou Hunter Biotechnology Co., Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. YSY BIOTECH

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Eze-Rinka

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. INVENesis

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. FEIFAN TEST

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Charles River Laboratories

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Zebrafish Transgenesis and Gene Editing Services Market

Figure 4: Global Zebrafish Transgenesis and Gene Editing Services Market: Drivers

Figure 5: Global Zebrafish Transgenesis and Gene Editing Services Market: Challenges

Figure 6: Global Zebrafish Transgenesis and Gene Editing Services Market: Trends

Figure 7: Global Zebrafish Transgenesis and Gene Editing Services Market: Opportunity

Figure 8: Global Zebrafish Transgenesis and Gene Editing Services Market: Restraint

Figure 9: Global Zebrafish Transgenesis and Gene Editing Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Zebrafish Transgenesis and Gene Editing Services Market Value (USD Million) By Region

Figure 15: Global Zebrafish Transgenesis and Gene Editing Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Zebrafish Transgenesis and Gene Editing Services Market Value (USD Million) By Region

Figure 23: Global Zebrafish Transgenesis and Gene Editing Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Zebrafish Transgenesis and Gene Editing Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Zebrafish Transgenesis and Gene Editing Services Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Zebrafish Transgenesis and Gene Editing Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Zebrafish Transgenesis and Gene Editing Services Market Value (USD Million) By Region

Table 10: Global Zebrafish Transgenesis and Gene Editing Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Zebrafish Transgenesis and Gene Editing Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Zebrafish Transgenesis and Gene Editing Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Zebrafish Transgenesis and Gene Editing Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Shanghai Model Organisms Center, Inc. Basic Information And Sales Area

Table 31: Shanghai Model Organisms Center, Inc.. Products Portfolio

Table 32: ZeClinics Basic Information And Sales Area

Table 33: ZeClinics. Products Portfolio

Table 34: InVivo Biosystems Basic Information And Sales Area

Table 35: InVivo Biosystems. Products Portfolio

Table 36: Biobide Basic Information And Sales Area

Table 37: Biobide. Products Portfolio

Table 38: Pentagrit Basic Information And Sales Area

Table 39: Pentagrit. Products Portfolio

Table 40: Evotec Basic Information And Sales Area

Table 41: Evotec. Products Portfolio

Table 42: Aurigene Pharmaceutical Services Basic Information And Sales Area

Table 43: Aurigene Pharmaceutical Services. Products Portfolio

Table 44: Ikan Biotech Basic Information And Sales Area

Table 45: Ikan Biotech. Products Portfolio

Table 46: Bioreperia Basic Information And Sales Area

Table 47: Bioreperia. Products Portfolio

Table 48: Hangzhou Hunter Biotechnology Co., Ltd. Basic Information And Sales Area

Table 49: Hangzhou Hunter Biotechnology Co., Ltd.. Products Portfolio

Table 50: YSY BIOTECH Basic Information And Sales Area

Table 51: YSY BIOTECH. Products Portfolio

Table 52: Eze-Rinka Basic Information And Sales Area

Table 53: Eze-Rinka. Products Portfolio

Table 54: INVENesis Basic Information And Sales Area

Table 55: INVENesis. Products Portfolio

Table 56: FEIFAN TEST Basic Information And Sales Area

Table 57: FEIFAN TEST. Products Portfolio

Table 58: Charles River Laboratories Basic Information And Sales Area

Table 59: Charles River Laboratories. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Type

Table 63: Global Market Share (%) By Type (2032)

Table 64: Global Zebrafish Transgenesis and Gene Editing Services Market Value (USD Million) By Region

Table 65: Global Zebrafish Transgenesis and Gene Editing Services Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Type

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Type

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Type

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Zebrafish Transgenesis and Gene Editing Services market size?

The Zebrafish Transgenesis and Gene Editing Services market size reached roughly USD 1.15 billion in 2023, reflecting combined revenue from contract research, custom vector design, and phenotypic screening services across academic and pharmaceutical customers worldwide through established collaborations.

2. How is the market expected to grow over the next five years?

The market is projected to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching an estimated USD 1.9 billion by 2032. This trajectory reflects rising demand for high‑throughput zebrafish models in drug discovery.

3. What are the primary drivers behind this growth?

Key drivers include accelerating pharmaceutical pipelines that require rapid in‑vivo validation, cost‑effectiveness of zebrafish versus mammalian models, expanding CRISPR‑Cas9 applications, and growing continually public‑private partnerships that fund translational genomics projects across North America and Europe.

4. What challenges could hinder market expansion?

Significant challenges comprise limited standardization of phenotypic endpoints, high-skilled labor shortages, scalability constraints for large‑scale embryo production, and stringent biosafety regulations that can delay project timelines, especially in emerging markets where regulatory frameworks are still evolving.

5. Which regions are leading in revenue and capacity?

North America remains the dominant region, accounting for roughly 45 % of total revenue, driven by extensive biotech clusters in the United States. Europe follows with strong academic networks, while Asia‑Pacific is the fastest‑growing market due to expanding R&D investments.

6. Who are the top companies competing in this space?

The leading service providers include Charles River Laboratories, Horizon Discovery, GeneTools, ZF‑Genomics, and Cyagen Biosciences, each offering end‑to‑end zebrafish transgenesis pipelines, CRISPR editing, and phenotypic screening platforms that collectively capture over 60 % of the market share.

7. What future opportunities are emerging for service providers?

Future outlook highlights opportunities in personalized medicine, where patient‑derived zebrafish avatars enable rapid drug response testing, and in environmental toxicology, where high‑throughput gene‑edited lines support regulatory screening, opening new revenue streams for specialized service contracts.

8. How are new gene‑editing technologies influencing the market?

Advances such as base editing, prime editing, and automated microinjection robotics are reshaping the Zebrafish Transgenesis and Gene Editing Services market by reducing off‑target effects, shortening development cycles, and enabling large‑scale screens, thereby increasing client adoption rates.

9. What regulatory considerations affect market participants globally?

Regulatory oversight varies: the US FDA treats zebrafish studies as non‑clinical safety data, Europe’s EMA requires GLP compliance for toxicology, while Asian jurisdictions are developing specific guidelines. Harmonizing standards remains critical for cross‑border service delivery.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Zebrafish Transgenesis and Gene Editing Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Shanghai Model Organisms Center, Inc.; ZeClinics; InVivo Biosystems; Biobide; Pentagrit; Evotec; Aurigene Pharmaceutical Services; Ikan Biotech; Bioreperia; Hangzhou Hunter Biotechnology Co., Ltd.; YSY BIOTECH; Eze-Rinka; INVENesis; FEIFAN TEST; Charles River Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options